Sturrock, Beattie R H, Milne, Kate and Chevassut, Timothy J T (2020) The Renin-Angiotensin system – a therapeutic target in COVID-19? Clinical Medicine. pp. 1-4. ISSN 1470-2118

	Microsoft Word (DOCX) (Review) Restricted to SRO admin only Download (286kB)
	PDF - Published Version Restricted to SRO admin only until 16 May 2021. Download (107kB)

Abstract

COVID-19, caused by infection with SARS-CoV-2, is a disease characterised by cough, fever and fatigue, which progresses to life-threatening lung injury in approximately 5% of patients. The SARS-CoV-2 virus enters the cell via ACE2. ACE2 is a component of the renin–angiotensin system (RAS) which has an important counterregulatory effect on the classical ACE-dependent pathway. Several antihypertensives increase ACE2 expression or activity, leading to concern that this may facilitate SARS-CoV-2 entry and worsen COVID-19 disease. However, ACE2 is protective against lung injury while ANG II (which is catabolised by ACE2) is associated with lung injury both in mice and humans. We propose that medications which inhibit the RAS ACE-dependent pathway may be beneficial in treating COVID-19 and should be explored in animal models and clinical trials. Here we give an overview of the RAS pathway with respect to COVID-19 and argue that strategies which manipulate this pathway might reduce the destructive lung manifestations of COVID-19 and improve patient outcomes.

Item Type:	Article
Schools and Departments:	Brighton and Sussex Medical School > Clinical and Experimental Medicine
Subjects:	R Medicine R Medicine > RM Therapeutics. Pharmacology R Medicine > RM Therapeutics. Pharmacology > RM0300 Drugs and their actions
Depositing User:	Timothy Chevassut
Date Deposited:	23 Jun 2020 08:18
Last Modified:	23 Jun 2020 08:30
URI:	http://sro.sussex.ac.uk/id/eprint/92076

View download statistics for this item

📧 Request an update